Royal Bank of Canada
CTXR icon

Royal Bank of Canada’s Citius Pharmaceuticals CTXR Stock Holding History

Royal Bank of Canada’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,000
Closed -$16K – 6875
2024
Q4 		$16K Buy
+4,000
New +$26.9K ﹤0.01% 6191
2024
Q2 		– Sell
-121
Closed -$3K – 7127
2024
Q1 		$3K Sell
121
-1,464
-92% -$26.7K ﹤0.01% 6580
2023
Q4 		$30K Buy
1,585
+783
+98% +$14.8K ﹤0.01% 6180
2023
Q3 		$14K Buy
802
+303
+61% +$7.2K ﹤0.01% 6306
2023
Q2 		$15K Buy
+499
New +$16.4K ﹤0.01% 6325
2022
Q4 		– Sell
-3
Closed – – 7298
2022
Q3 		$0 Buy
+3
New +$82 ﹤0.01% 7499
2022
Q2 		– Sell
-304
Closed -$14K – 7416
2022
Q1 		$14K Sell
304
-627
-67% -$24.8K ﹤0.01% 6791
2021
Q4 		$36K Buy
931
+337
+57% +$15.3K ﹤0.01% 6552
2021
Q3 		$30K Buy
594
+282
+90% +$14.1K ﹤0.01% 6467
2021
Q2 		$27K Buy
+312
New +$18.8K ﹤0.01% 6394

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCA
Bay Colony Advisors Concord, Massachusetts $903M AUM 33.67% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Royal Bank of Canada's CTXR Position: Q1 2025 in Review

Royal Bank of Canada sold out of Citius Pharmaceuticals (CTXR) in Q1 2025, closing a stake of 4,000 shares — an estimated $16K sold.

Royal Bank of Canada first reported a position in CTXR in Q2 2021 and held it in 10 quarters. The position peaked at $36K in Q4 2021. 28 funds tracked by Wall St. Rank hold CTXR as of Q1 2025.

  • Royal Bank of Canada reported no remaining Citius Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 4,000 Citius Pharmaceuticals shares in Q1 2025, an estimated $16K.
  • Royal Bank of Canada first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Royal Bank of Canada's Citius Pharmaceuticals position peaked at $36K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.